NCT03134222 - Study to Evaluate Safety and Efficacy of Filgotinib and Lanraplenib in Females With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 24, 2017

Primary Completion Date

March 13, 2019

Study Completion Date

December 18, 2019

Conditions

Cutaneous Lupus Erythematosus

Interventions

DRUG

Lanraplenib

30 mg tablets administered orally once daily with or without food

DRUG

Filgotinib

200 mg tablets administered orally once daily with or without food

DRUG

Lanraplenib placebo

Tablets administered orally once daily with or without food

DRUG

Filgotinib placebo

Tablets administered orally once daily with or without food

Trial Locations (16)

17033

Penn State Hershey Medical Center, Hershey

19104

University of Pennsylvania, Philadelphia

27104

Wake Forest University Health Sciences, Winston-Salem

28210

DJL Clinical Research, PLLC, Charlotte

32713

Omega Research Consultants LLC, DeBary

33765

Clinical Research of West Florida, Inc., Clearwater

75231

Metroplex Clinical Research Center, Dallas

90045

Dermatology Research Associates, Los Angeles

90211

Wallace Rheumatic Studies Center, Beverly Hills

91786

Inland Rheumatology Clinical Trials, Upland

92103

Medderm Associates, San Diego

92260

Desert Medical Advances, Palm Desert

92835

St. Jude Hospital Yorba Linda DBA Dr. Joseph Heritage Healthcare, Fullerton

K2C 3N2

Dermatology Ottawa Research Centre, Ottawa

M5T 2S8

University Health Network (UHN) - Toronto Western Hospital, Toronto

N2J 1C4

K.Papp Clinical Research, Waterloo